Polio Vaccine Market Forecast, Shares and Latest Updates 2025

Market Size of Polio Vaccine Market

2023 Baseline:

◉Estimated size USD 861.25 million in 2024.

◉Sets the stage for consistent demand due to global eradication commitments.

2025 Market Value:

◉Reaches USD 904.57 million, backed by mass immunization campaigns (e.g., Gaza vaccinating 603,000 children with nOPV2).

2034 Projection:

◉Expected to grow to USD 1,406.89 million, reflecting sustained public-private partnerships and expanded IPV production in Africa and Asia.

Growth Driver:

◉CAGR of 5.03% (2025–2034) indicates steady demand despite polio-free status in several countries, as ongoing outbreak control and travel immunization sustain the market.

Dose Demand Forecasts:

◉UNICEF projects 3.7–3.9 billion bOPV doses needed in 4 years, equating to $500 million expenditure globally.

Over 1 billion nOPV2 doses administered in 35+ countries over the last 3 years.

Market Trends

Eradication Campaigns Fuel Demand:

◉Initiatives like EPI, UIP, NRHM in India and GPEI globally keep vaccines indispensable.

◉In 2024, Guinea immunized 3.2M children via UNICEF campaigns.

Partnerships Boost Local Production:

◉Sanofi + Biovac collaboration (2024) → first IPV manufacturing in Africa.

◉Strengthens supply security and reduces import reliance.

Technology-driven Innovations:

◉Thermostable vaccines & next-gen IPV → minimize cold-chain dependency.

◉China approved msIPV (Vero Cell, Sabin strains) in 2024.

Government Funding Expands Access:

◉Canada pledged $111M to GPEI (2024–2027) → part of its $1B total support.

◉UK contributed £1.65B to GAVI (2021–2025) for global immunization.

Outbreak-Driven Market Activation:

◉74 global polio cases reported (GPEI data).

◉Sudan (2024) → launched emergency campaign against cVDPV2 outbreak.

AI’s Role in Polio Vaccine Market

Supply Chain Optimization

◉AI predicts optimal delivery routes in conflict zones or rural areas.

◉Reduces wastage, ensures cold chain integrity.

Disease Surveillance & Outbreak Prediction

◉ML models detect virus circulation in wastewater (as seen in Germany 2024).

◉AI integrates epidemiological & environmental data for real-time outbreak mapping.

Targeted Vaccination Campaigns

◉AI highlights low-coverage zones → enables rapid “ring vaccination” response.

◉Helps address vaccine hesitancy hotspots with tailored communication.

Clinical Research & Next-Gen Vaccines

◉AI accelerates IPV formulation optimization, mRNA-based vaccine design.

◉Shortens R&D cycle → faster regulatory approvals.

Global Resource Allocation

◉AI systems model dose requirement forecasts (e.g., UNICEF’s 3.7B doses need).

◉Prevents understocking in high-birth regions like India, Pakistan.

Regional Insights in Polio Vaccine Market

1. North America (Market Leader, 2024)

◉Strengths: Strong healthcare infrastructure, stockpiles, CDC surveillance.

◉U.S.: Continues high vaccination coverage despite polio-free status; contributes to GPEI.

◉Canada: Routine immunization + $111M GPEI funding → ensures ongoing demand.

2. Asia-Pacific (Fastest Growth)

◉Drivers: Large child population, rising healthcare spend, active outbreaks.

◉India: Mass campaigns (UIP, NRHM), rural immunization, high birth rates sustain demand.

◉China: NMPA-approved msIPV in 2024; major vaccine producer & consumer.

◉Pakistan & Afghanistan: Endemic polio → continuous OPV campaigns required.

3. Europe (Stable Market)

◉UK: Routine immunization + largest GAVI donor (funding £1.65B).

◉Germany: Detected VDPV2 in wastewater (2024) → ensures vigilance & steady demand.

◉Region-wide: Traveler & migrant vaccination maintains vaccine coverage.

4. Latin America (Rising CAGR)

◉Brazil: Polio-free 34 years, OPV coverage 86.55% in 2023 (up from 77.20%).

◉Mexico: Ongoing “National Public Health Week” drives catch-up vaccinations.

5. Middle East & Africa (Outbreak-Driven Market)

◉Sudan (2024): Emergency vaccination against cVDPV2.

◉Africa (Sanofi–Biovac partnership): First IPV local production → supply resilience.

Market Dynamics

Drivers:

◉Global eradication initiatives (GPEI, WHO, UNICEF).

◉Government funding (e.g., Canada $111M, UK £1.65B).

◉Over 1B nOPV2 doses in 35+ countries in 3 years.

Restraints:

◉Adverse effects (fever, rare VDPV cases).

◉Vaccine hesitancy driven by misinformation.

Opportunities:

◉Next-gen IPV & thermostable vaccines.

◉Needle-free delivery systems.

◉Scaling production in Africa & Asia (Sanofi–Biovac, Sinovac msIPV).

Top Companies in Polio Vaccine Market

Pfizer Inc.

◉Products: Expanding vaccine pipeline (incl. mRNA tech).

◉Strength: Global R&D powerhouse; proven vaccine scalability.

Sanofi

◉Products: IPV portfolio, OPV supply.

◉Strength: Strategic partnerships (Biovac Africa, 2024).

GSK plc

◉Overview: Global immunization leader; vaccines integrated into EPI programs.

◉Strength: Long-standing presence in pediatric vaccines.

Serum Institute of India

◉Products: IPV & OPV bulk production.

◉Strength: Largest vaccine manufacturer; cost-effective supply for LMICs.

BIO-MED & Haffkine Bio-Pharma (India)

◉Products: Local IPV/OPV supply.

◉Strength: Strong government backing in mass immunization campaigns.